Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma - LARVOL DELTA

Prescription patterns of comedications associated with drug-drug interactions risk in HCV-infected patients undergoing direct-acting antiviral treatment: an analysis of an administrative claims database in Japan. (PubMed, J Pharm Health Care Sci) - "A considerable proportion of patients were prescribed medications with DDI risk during DAA treatment. A small but notable proportion of patients were on "Contraindication (Red)" medications. Consideration of the potential DDI risks associated with comedications by healthcare professionals is advised, referring not only to package inserts but also tools such as Liverpool HEP checker to guide safe prescribing when initiating DAA therapy for HCV patients."

Journal • Hepatitis C • Hepatology • Infectious Disease • Inflammation

Efficacy and safety of glecaprevir/pibrentasvir in acute HCV participants with a history of prior infection(s) (EASL 2025) - No abstract available

Clinical • Hepatitis C • Infectious Disease

8 weeks of Glecaprevir/Pibrentasvir is highly effective in patients with genotype 3 hepatitis C related cirrhosis, irrespective of the presence of clinically significant portal hypertension (EASL 2025) - No abstract available

Clinical • Cardiovascular • Fibrosis • Hepatitis C • Hepatology • Immunology • Infectious Disease • Inflammation • Portal Hypertension

Glecaprevir/pibrentasvir in chronic HCV: an integrated analysis of patients on concomitant opioids, antipsychotics and cardiovascular medications (EASL 2025) - No abstract available

Clinical • Cardiovascular • CNS Disorders • Hepatitis C

Efficacy and safety of glecaprevir/pibrentasvir in acute HCV participants with a history of prior infection(s) (EASL 2025) - No abstract available

Clinical • Hepatitis C • Infectious Disease

Real-world efficacy and safety of universal 8-week Glecaprevir/Pibrentasvir in CHC patients with early CKD or Pre-ESRD: insights from a nationwide HCV registry in Taiwan (EASL 2025) - No abstract available

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Chronic Kidney Disease • Hepatitis C • Renal Disease

Pre-Transplant Initiation of Direct-Acting Antiviral Therapy for Donor-Derived Hepatitis C in a Pediatric Patient (ISHLT 2025) - "She started the first dose of glecaprevir/pibrentasvir (GLE/PIB; 300 mg/120mg) approximately 8 hours prior to transplant operating room arrival...Knowing HCV transmission can occur, it is important to consider pre-transplant DAA pharmacokinetics/pharmacodynamics and potential effects of cardiac bypass, among other factors. Ascertaining donor viral load and delineating early post-transplant viral load kinetics in the recipient could be important in guiding optimal dosing and timing of DAA before transplant and in guiding DAA duration post-transplant."

Clinical • Pre-transplantation • Cardiomyopathy • Cardiovascular • Hepatitis C • Hepatology • Infectious Disease • Inflammation • Pediatrics • Transplantation

Evaluation of Glecaprevir/Pibrentasvir Use for Cardiothoracic Transplant Recipients of HCV NAT+ Organs (ISHLT 2025) - "Patient characteristics can be seen in Table 1 and additional results can be found in Table 2.Conclusion Despite extended hospitalization and high incidence of GP administration via enteral tube, this complex cohort still had rapid HCV viral clearance. This study suggests that, given GP efficacy in high acuity patients and associated inpatient costs, it is reasonable to consider literature exploring GP durations less than 8 weeks."

Clinical • Hepatitis C • Transplantation

A Case Report of a Rapid Development of Hepatocellular Carcinoma (HCC) Within Six Months of Hepatitis C Cure in an Individual With Risk Factors. (PubMed, Cureus) - "He was successfully treated with a six-month course of glecaprevir/pibrentasvir with eradication of the virus. Before the primary care practitioner (PCP) visit, the patient had an ED visit for abdominal pain and chronic constipation, during which he underwent a non-contrast CT of the abdomen, with an incidental finding of a 2.4 cm liver mass in the right hepatic lobe. It was followed up with an MRI and CT-guided biopsy, the results of which showed poorly differentiated HCC."

Journal • Chronic Kidney Disease • Constipation • Diabetes • Fibrosis • Gastroenterology • Gastrointestinal Cancer • Gastrointestinal Disorder • Hepatitis C • Hepatocellular Cancer • Hepatology • Immunology • Infectious Disease • Metabolic Disorders • Nephrology • Oncology • Pain • Renal Disease • Solid Tumor

Simplified HCV Treatment for Eligible Patients with Pan-Genotypic Regimens (APASL 2025) - "Pangenotypic DAAs, i.e. glecaprevir/pibrentasvir for 8 weeks or sofosbuvir/velpatasvir for 12 weeks, should be used to simplify the treatment. Assessment for other causes of liver disease is recommended for patients with elevated transaminase levels after achieving sustained virologic response. Patients with advanced liver fibrosis who achieve sustained virologic response should undergo surveillance for HCC every 6 months by means of imaging and serum tumor markers."

Clinical • Chronic Kidney Disease • Fibrosis • Gastroenterology • Hepatitis B • Hepatitis C • Hepatocellular Cancer • Hepatology • Human Immunodeficiency Virus • Immunology • Liver Cirrhosis • Liver Failure • Nephrology • Oncology • Renal Disease • Solid Organ Transplantation • Solid Tumor

Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir for the Retreatment of Chronic Hepatitis C Patients with DAA Relapse (APASL 2025) - "The impact of gender, age, cirrhosis status, genotype, and the addition of ribavirin during treatment on HCV RNA clearance rates was assessed...Additionally, among the 58 relapsed patients, 22 patients had previously been treated with SOF/VEL, and 18 patients had been treated with Glecaprevir/Pibrentasvir... SOF/VEL/VOX is an effective and safe retreatment option for HCV patients who relapse after DAA therapy, demonstrating excellent virological response rates and good tolerability."

Clinical • Fibrosis • Gastrointestinal Disorder • Hepatitis C • Hepatology • Infectious Disease • Inflammation

Glecaprevir/Pibrentasvir in HIV/HCV-coinfected patients treated with bictegravir (APASL 2025) - "One of the most commonly used highly active antiretroviral therapy (HAART) is bictegravir/emtricitabine/tenofovir alafenamide (B/FTC/TAF). It has been proven that coadministration of B/FTC/TAF and sofosbuvir/velpatasvir (SOF/VEL) is unlikely to induce clinically significant interactions, however, coadministration of B/FTC/TAF with gelcaprevir/pibrentasvir (GLE/PIB) has not been studied...Of these, 38 were treated with GLE/PIB and 101 were treated with SOF/VEL ± ribavirin (RBV)... To our knowledge, this is one of the first studies to assess the real-life effectiveness and safety of GLE/PIB in HIV/HCV-positive patients treated with bictegravir. The study showed that real-life results of therapy with GLE/PIB or SOF/VEL did not differ significantly in HIV/HCV-coinfected patients treated with B/FTC/TAF. Both regimens allowed encouraging SVR12 rates and treatment safety, as well as tolerability, were also comparable between the study groups."

Clinical • Hepatitis C • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Inflammation • Liver Failure

Drug-drug interactions associated with comedication in patients with Hepatitis C virus undergoing direct-acting antivirals: An analysis of administrative claims database in Japan (APASL 2025) - "Patients who initiated DAA therapy (SOF/VEL or GLE/PIB) were identified from the data between April 2017 to August 2023... A considerable proportion of patients were prescribed medications with DDI risk during DAA treatment. A small but notable proportion of patients were on "Do not co-administer (Red)" medications. Consideration of the potential DDI risks associated with comedications by healthcare professionals is advised, referring not only to package inserts but also tools such as the HEP checker to guide safe prescribing when initiating DAA therapy for HCV patients."

Claims database • Clinical • Hepatitis C • Hepatology • Infectious Disease • Inflammation

Direct-Acting Antiviral Treatment Failure and Retreatment Strategies Following Hepatitis C-Positive Solid Organ Transplantation in Hepatitis C-Negative Recipients: A Multicenter Case Series. (PubMed, Transpl Infect Dis) - "Despite initial DAA failures, all HCV-negative SOT recipients achieved SVR following one or more courses of retreatment with DAAs."

Journal • Hepatitis C • Hepatology • Infectious Disease • Inflammation • Solid Organ Transplantation • Transplantation

A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients (clinicaltrials.gov) - P4 | N=200 | Active, not recruiting | Sponsor: Mayo Clinic | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2024 ➔ Dec 2025

Enrollment closed • Trial completion date • Hepatitis C • Hepatology • Infectious Disease • Inflammation • Solid Organ Transplantation • Transplantation

Preclinical Pharmacokinetic Assessment of a Long-Acting Solid Injectable for Hepatitis C Virus (CROI 2025) - "Methods Glecaprevir and pibrentasvir were formulated using a spray drying technology and processed to form a 11 mm x 2 mm solid using vacuum compression moulding...High concentrations were achieved rapidly after administration possibly mitigating the need for oral lead-in which would be sub-optimal for treatment of chronic infection. Further work is required to understand variability in pharmacokinetic exposure of solid injectables relative to their liquid counterparts, and acceptability of the solid injectable approach to patients."

PK/PD data • Preclinical • Hepatitis C • Hepatology • Infectious Disease • Inflammation

Safety and Efficacy of 8-Week Glecaprevir/Pibrentasvir for Acute HCV in People Living With HIV (CROI 2025) - "The most common HIV treatment contained bictegravir (59/144, 41.0%). Conclusions An 8-week treatment with G/P was safe and effective in PLHIV with acute HCV infection. Concomitant HIV antiretrovirals maintained HIV suppression and were safe to use with G/P."

Clinical • Late-breaking abstract • Hepatitis C • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Inflammation • Liver Failure

Using HCV NAT-positive Kidneys to Expand the Deceased Donor Pool: A Single-Center Experience (NKF-SCM 2025) - "Waiting times were compared to national data using the United States Renal Data System as well as CPMC outcomes from the Scientific Registry of Transplant Recipients database.Results • Demographics: 50% male; mean age 52 years; ABO blood types - 47% A, 44% O, 6% B, 3% AB • 73.3% of D+/R- blood type A recipients were transplanted within three years of their listing vs. 21.5% of D-/R- recipients • 71.4% of D+/R- blood type O recipients were transplanted within three years vs. 14.3% of D-/R- recipients • HCV transmission rate was 100% • Treatment modalities: 78% sofosbuvir/velpatasvir, 22% glecaprevir/pibrentasvir • Mean virus clearance time was 25 days • Mean post-transplant creatinines at 3 and 6 months were 1.31 mg/dL and 1.12 mg/dL, respectivelyConclusion Despite the small sample size, the results of this study demonstrate the ability of HCV D+/R- allografts to provide well-functioning kidneys to recipients without long-term HCV risk. On the average, these patients..."

Clinical • Hepatitis C • Hepatology • Infectious Disease • Inflammation

A Case of MALA Despite Therapeutic Metformin Level and Normal Renal Function (NKF-SCM 2025) - "We present a case of MALA with profound lactic acidosis despite therapeutic plasma metformin (MTF) level and normal renal function.Methods A 55-year-old female with past medical history of type 2 diabetes on MTF 1,000mg BID (stable dose since 2022), hypertension, hepatitis C s/p Mavyret, chronic iron deficiency anemia, hyperlipidemia, and obesity presented with worsening shortness of breath...Further workup was unrevealing other than positive streptococcus pneumonia urine antigen for which she was treated with IV ceftriaxone...Concomitant factors in our case were severe anemia and sepsis. Rapid resolution of lactic acidosis was achieved with HD and treatment of anemia and infection."

Clinical • Anemia • Cardiovascular • Diabetes • Diabetic Nephropathy • Dyslipidemia • Genetic Disorders • Hematological Disorders • Hepatitis C • Hepatology • Hypertension • Immunology • Infectious Disease • Inflammation • Metabolic Disorders • Nephrology • Obesity • Pneumococcal Infections • Pneumonia • Renal Disease • Respiratory Diseases • Septic Shock • Type 2 Diabetes Mellitus

Direct-acting antiviral treatment outcomes in people infected with endemic compared to epidemic hepatitis C virus subtypes in England. (PubMed, J Infect) - "This study provides further evidence that endemic HCV subtypes lead to sub-optimal DAA efficacy, which may impact global HCV elimination."

Journal • Hepatitis C • Hepatology • Infectious Disease • Inflammation

Implementation of Glecaprevir-Pibrentasvir for Children Aged 3-12 Years With Chronic Hepatitis C: Multicentre Israeli Experience. (PubMed, Acta Paediatr) - No abstract available

Journal • Hepatitis C • Hepatology • Infectious Disease • Inflammation

HCV Test and Treat Utilizing Simplified HCV Patient Education (clinicaltrials.gov) - P4 | N=8 | Terminated | Sponsor: Weill Medical College of Cornell University | N=200 ➔ 8 | Trial completion date: Oct 2027 ➔ Nov 2024 | Recruiting ➔ Terminated | Trial primary completion date: Oct 2027 ➔ Nov 2024; The funding was halted.

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Hepatitis C • Hepatology • Infectious Disease • Inflammation

Prophylactic Treatment of Hepatitis C Virus Infection After Kidney Transplantation with the Combination of Glecaprevir/Pibrentasvir and Sofosbuvir in a Highly Sensitized Hepatitis C Virus-Negative Recipient: A Case Report and Review of the Literature. (PubMed, Biomedicines) - " Each transplant center should decide on the selection of candidates for kidney transplantation from HCV RNA-positive donors to HCV-negative recipients, the availability and choice of DAA treatment, and post-transplant follow-up. Our case emphasizes the need for early DAA treatment based on viral load and HCV genotyping, as well as for careful post-transplant surveillance including protocol biopsies."

Journal • Hepatitis C • Hepatology • Infectious Disease • Inflammation • Transplantation

The Effects of Pangenotypic Direct-Acting Antiviral Therapy on Lipid Profiles and Insulin Resistance in Chronic Hepatitis C Patients. (PubMed, Viruses) - "This study examined how two pangenotypic DAA regimens, glecaprevir/pibrentasvir (GLE/PIB) and sofosbuvir/velpatasvir (SOF/VEL), affect lipid profiles and insulin resistance after viral eradication in chronic HCV patients. Both pangenotypic DAA regimens significantly impact lipid profiles, particularly LDL and TC, but not insulin resistance. This study emphasizes the need for more research into the long-term metabolic effects of DAAs."

Journal • Retrospective data • Dyslipidemia • Hepatitis C • Hepatology • Infectious Disease • Inflammation • Metabolic Disorders

A Comprehensive Review of Antiviral Therapy for Hepatitis C: The Long Journey from Interferon to Pan-Genotypic Direct-Acting Antivirals (DAAs). (PubMed, Viruses) - "When combined with ribavirin, peg-IFN achieved higher SVR rates, especially in non-genotype 1 HCV infections, but the combination also brought additional side effects, such as anemia and depression. The advent of the first-generation DAAs, such as telaprevir and boceprevir, marked a significant milestone...Second-generation DAAs, like sofosbuvir and ledipasvir, introduced IFN-free regimens with improved safety profiles and efficacy. The most recent advances are pan-genotypic DAAs, including glecaprevir-pibrentasvir and sofosbuvir-velpatasvir, which offer high SVR rates across all genotypes, shorter treatment durations, and fewer side effects. Current pan-genotypic regimens represent a cornerstone in HCV therapy, providing an accessible and effective solution globally."

Journal • Review • CNS Disorders • Depression • Hematological Disorders • Hepatitis C • Hepatology • Infectious Disease • Inflammation • Psychiatry